Abstract:The equine infectious anemia virus (EIAV) attenuated vaccine was developed by long-term passaging of a field-isolated virulent strain in cross-species hosts, followed by successive cultivation in cells in vitro To explore the molecular mechanism underlying the evolution of the EIAV attenuated vaccine, a systematic study focusing on long-terminal-repeat (LTR) variation in numerous virus strains ranging from virulent EIAV to attenuated EIAV was performed over time both in vitro and in vivo Two hypervariable regions were identified within the U3 region in the enhancer region (EHR) and the negative regulatory element (NRE) and within the R region in the transcription start site (TSS) and the Tat-activating region (TAR). Among these sites, variation in the U3 region resulted in the formation of additional transcription factor binding sites; this variation of the in vitro-adapted strains was consistent with the loss of pathogenicity. Notably, the same LTR variation pattern was observed both in vitro and in vivo Generally, the LTR variation in both the attenuated virus and the virulent strain fluctuated over time in vivo Interestingly, the attenuated-virus-specific LTR variation was also detected in horses infected with the virulent strain, supporting the hypothesis that the evolution of an attenuated virus might have involved branching from EIAV quasispecies. This hypothesis was verified by phylogenetic analysis. The present systematic study examining the molecular evolution of attenuated EIAV from EIAV quasispecies may provide an informative model reflecting the evolution of similar lentiviruses.IMPORTANCE The attenuated EIAV vaccine was the first lentiviral vaccine used to successfully control for equine infectious anemia in China. This vaccine provides an important reference for studying the relationship between EIAV gene variation and changes in biological characteristics. Importantly, the vaccine provides a model for the investigation of lentiviral quasispecies evolution. This study followed the "natural" development of the attenuated EIAV vaccine by use of a systematic analysis of LTR evolution in vitro and in vivo The results revealed that the increase in LTR variation with passaging was accompanied by a decrease in virulence, which indicated that LTR variability might parallel the attenuation of virulence. Interestingly, the attenuated-virus-specific LTR variation was also detected in virulent-strain-infected horses, a finding consistent with those of previous investigations of gp90 and S2 evolution. Therefore, we present a hypothesis that the evolution of the attenuated virus may involve branching from EIAV quasispecies present in vivo.

Reverse Mutation of the Virulence-Associated S2 Gene Does Not Cause an Attenuated Equine Infectious Anemia Virus Strain to Revert to Pathogenicity

A unique evolution of the s2 gene of equine infectious anemia virus in hosts correlated with particular infection statuses.

Construction of EIAV Infectious Clone with S2 Gene Dominant Negative Mutation

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV

Amino Acid Mutations of the Infectious Clone from Chinese EIAV Attenuated Vaccine Resulted in Reversion of Virulence.

An Attenuated EIAV Vaccine Strain Induces Significantly Different Immune Responses from Its Pathogenic Parental Strain Although with Similar in Vivo Replication Pattern

C-terminal Truncation of the Transmembrane Protein of an Attenuated Lentiviral Vaccine Alters Its in Vitro but Not in Vivo Replication and Weakens Its Potential Pathogenicity

A Proviral Derivative from a Reference Attenuated EIAV Vaccine Strain Failed to Elicit Protective Immunity

Amino Acid Substitutions in the Structural or Nonstructural Proteins of A Vaccine Strain of Equine Arteritis Virus Are Associated with Its Attenuation

Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies in Vitro and in Vivo.

Generation of VP5 deficient mutant of infectious bursal disease virus strain HZ2

Genetic Evolution of Equine Infectious Anemia Virus LTR Region During Attenuation in Vitro.

In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine

Long Terminal Repeat Sequences from Virulent and Attenuated Equine Infectious Anemia Virus Demonstrate Distinct Promoter Activities.

Genetic Variation in the Long Terminal Repeat Associated with the Transition of Chinese Equine Infectious Anemia Virus from Virulence to Avirulence

Amino Acid Mutations in the Env Gp90 Protein That Modify N-linked Glycosylation of the Chinese EIAV Vaccine Strain Enhance Resistance to Neutralizing Antibodies.

Structural and Biochemical Insights into the V/I505T Mutation Found in the EIAV Gp45 Vaccine Strain

Transient Immune Suppression of Inapparent Carrier Ponies Inoculated with Attenuated Equine Infectious Anemia Virus Infectious Clone.

Attenuation of the virulence of a recombinant influenza virus expressing the naturally truncated NS gene from an H3N8 equine influenza virus in mice

Deletion of a 7-amino-acid region in the porcine epidemic diarrhea virus envelope protein induces higher type I and III interferon responses and results in attenuation <i>in vivo</i>

Newcastle disease vaccine virus I-2 fails to acquire virulence during repeated passage in vivo